Cefiderocol

Authors

  • Aurélien Dinh Service des maladies infectieuses et tropicales, Hôpital Raymond-Poincaré, AP-HP Université Paris-Saclay, 104 bd Raymond Poincaré, 92380 Garches
  • Julien Massol Service des maladies infectieuses et tropicales, Hôpital Raymond-Poincaré, AP-HP Université Paris-Saclay, 104 bd Raymond Poincaré, 92380 Garches
  • Clara Duran Service des maladies infectieuses et tropicales, Hôpital Raymond-Poincaré, AP-HP Université Paris-Saclay, 104 bd Raymond Poincaré, 92380 Garches
  • Frédérique Bouchand Pharmacie, Hôpital Raymond-Poincaré, AP-HP Université Paris-Saclay, 104 bd Raymond Poincaré, 92380 Garches
  • Laurent Dortet Service de microbiologie, Centre National de Référence de la Résistance aux Antibiotiques, Hôpital Bicêtre, AP-HP Université Paris-Saclay, 78 Rue du Général Leclerc, 94270 Le Kremlin Bicêtre

DOI:

https://doi.org/10.37051/mir-00130

Keywords:

cefiderocol, bacterial resistance, sepsis, healthcare-associated infections

Abstract

Intravenous cefiderocol, commercialized under the name Fetcroja®, is the first siderophore cephalosporin on the market. It was approved by the Haute Autorité de Santé (HAS) for severe infections due to multi-drug resistant Gram-negative bacilli (MDR GNB) when therapeutic options are limited. Indeed, cefiderocol is effective in vitro against the four types of β-lactamases according to the Ambler classification, including metallo-β-lactamases, et shows excellent activity against most GNB, in particular MDR isolates.

In several randomized double-blind trials, cefiderocol showed non-inferiority compared to imipenem/cilastatine in complicated urinary tract infections and to meropenem in health care-associated pneumonia. In a trial on carbapenem-resistant pathogens, cefiderocol demonstrated an activity comparable to the best treatment available, but mortality rate was higher in the cefiderocol arm. Furthermore, cefiderocol seems to be well-tolerated, with only few adverse events found in the randomized trials.

Cefiderocol is a novel molecule effective against MDR GNB, that represents a new therapeutic option in treating complex infections.

Image

Published

2022-09-23

How to Cite

Dinh, A., Massol, J., Duran, C., Bouchand, F., & Dortet, L. (2022). Cefiderocol. Médecine Intensive Réanimation. https://doi.org/10.37051/mir-00130

Issue

Section

Expert Opinion